All patients
Age > 65y BCLC B BCLC C ECOG 0 ECOG 1 Gender, female Gender, male viral status HBV viral status HCV viral status uninfected
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic/advanced hepatocellular cancer (mHCC), atezolizumab based treatment vs. VEGF(R) inhibitor, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMbrave-150, 2020 0.58 [0.42; 0.80]
0.58 [0.42 ; 0.80 ] IMbrave-150, 2020 1 0% 501 NA not evaluable progression or deaths (PFS)detailed results IMbrave-150, 2020 0.59 [0.46; 0.75]
0.59 [0.46 ; 0.75 ] IMbrave-150, 2020 1 0% 501 NA not evaluable objective responses (ORR)detailed results IMbrave-150, 2020 2.77 [1.62; 4.73]
2.77 [1.62 ; 4.73 ] IMbrave-150, 2020 1 0% 501 NA not evaluable AE (any grade)detailed results IMbrave-150, 2020 0.70 [0.14; 3.50]
0.70 [0.14 ; 3.50 ] IMbrave-150, 2020 1 0% 485 NA not evaluable AE (grade 3-4)detailed results IMbrave-150, 2020 1.06 [0.72; 1.55]
1.06 [0.72 ; 1.55 ] IMbrave-150, 2020 1 0% 485 NA not evaluable AE leading to death (grade 5)detailed results IMbrave-150, 2020 0.78 [0.33; 1.82]
0.78 [0.33 ; 1.82 ] IMbrave-150, 2020 1 0% 485 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results IMbrave-150, 2020 1.61 [0.88; 2.92]
1.61 [0.88 ; 2.92 ] IMbrave-150, 2020 1 0% 485 NA not evaluable SAE (any grade)detailed results IMbrave-150, 2020 1.38 [0.92; 2.07]
1.38 [0.92 ; 2.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Abdominal pain AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.12; 1.90]
0.47 [0.12 ; 1.90 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Acute kidney injury AE (grade 3-4)detailed results IMbrave-150, 2020 0.16 [0.02; 1.51]
0.16 [0.02 ; 1.51 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Alopecia AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.01; 23.97]
0.47 [0.01 ; 23.97 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Anaemia AE (grade 3-4)detailed results IMbrave-150, 2020 1.07 [0.32; 3.53]
1.07 [0.32 ; 3.53 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Asthenia AE (grade 3-4)detailed results IMbrave-150, 2020 0.12 [0.01; 1.05]
0.12 [0.01 ; 1.05 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Constipation AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.01; 23.97]
0.47 [0.01 ; 23.97 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Cough AE (grade 3-4)detailed results IMbrave-150, 2020 0.24 [0.01; 7.07]
0.24 [0.01 ; 7.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Decreased appetite AE (grade 3-4)detailed results IMbrave-150, 2020 0.31 [0.09; 1.11]
0.31 [0.09 ; 1.11 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Diarrhoea AE (grade 3-4)detailed results IMbrave-150, 2020 0.34 [0.12; 1.01]
0.34 [0.12 ; 1.01 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Dyspepsia AE (grade 3-4)detailed results IMbrave-150, 2020 0.12 [0.01; 2.61]
0.12 [0.01 ; 2.61 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMbrave-150, 2020 0.63 [0.14; 2.84]
0.63 [0.14 ; 2.84 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Epistaxis AE (grade 3-4)detailed results IMbrave-150, 2020 0.24 [0.01; 7.07]
0.24 [0.01 ; 7.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Fatigue AE (grade 3-4)detailed results IMbrave-150, 2020 0.75 [0.24; 2.34]
0.75 [0.24 ; 2.34 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Hypertension AE (grade 3-4)detailed results IMbrave-150, 2020 1.29 [0.73; 2.28]
1.29 [0.73 ; 2.28 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Increase AST AE (grade 3-4)detailed results IMbrave-150, 2020 1.39 [0.61; 3.18]
1.39 [0.61 ; 3.18 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMbrave-150, 2020 2.91 [0.64; 13.19]
2.91 [0.64 ; 13.19 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Infusion-related reaction AE (grade 3-4)detailed results IMbrave-150, 2020 7.75 [0.44; 135.83]
7.75 [0.44 ; 135.83 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Nausea AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.03; 7.61]
0.47 [0.03 ; 7.61 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results IMbrave-150, 2020 0.02 [0.00; 0.28]
0.02 [0.00 ; 0.28 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Proteinuria AE (grade 3-4)detailed results IMbrave-150, 2020 4.86 [0.62; 38.30]
4.86 [0.62 ; 38.30 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Pruritus AE (grade 3-4)detailed results IMbrave-150, 2020 0.47 [0.01; 23.97]
0.47 [0.01 ; 23.97 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMbrave-150, 2020 0.95 [0.17; 5.23]
0.95 [0.17 ; 5.23 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Rash AE (grade 3-4)detailed results IMbrave-150, 2020 0.06 [0.00; 1.10]
0.06 [0.00 ; 1.10 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMbrave-150, 2020 0.95 [0.23; 3.84]
0.95 [0.23 ; 3.84 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Vomiting AE (grade 3-4)detailed results IMbrave-150, 2020 0.95 [0.09; 10.54]
0.95 [0.09 ; 10.54 ] IMbrave-150, 2020 1 0% 485 NA not evaluable Weight decreased AE (grade 3-4)detailed results IMbrave-150, 2020 0.24 [0.01; 7.07]
0.24 [0.01 ; 7.07 ] IMbrave-150, 2020 1 0% 485 NA not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 06:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 40,132,131,133
- treatments: 851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866